Milestone Pharmaceuticals Inc. Interest Receivable, Current
Milestone Pharmaceuticals Inc. (MIST) had Interest Receivable, Current of $528.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Nontrade Receivables › Nontrade Receivables, Current
us-gaap:InterestReceivableCurrent · last filed 2026-08-12
- 2026-06-30: Interest Receivable, Current $528.00K.
- 2026-03-31: Interest Receivable, Current $1.19M.
- 2025-12-31: Interest Receivable, Current $196.00K.
- 2025-09-30: Interest Receivable, Current $398.00K.
| Period end | Interest Receivable, Current |
|---|---|
| 2026-06-30 | $528.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.19M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $196.00K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $398.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $113.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $342.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $604.00K 10-K · filed 2026-03-20 |
| 2024-09-30 | $1.06M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $973.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $813.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $528.00K 10-K · filed 2025-03-13 |
| 2022-12-31 | $615.00K 10-K · filed 2024-03-21 |
| 2019-03-31 | $162.00K 10-Q · filed 2019-06-19 |
| 2018-12-31 | $178.00K 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |